PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform...

Full description

Bibliographic Details
Main Authors: Ben Fulton, Susan C. Short, Allan James, Stefan Nowicki, Catherine McBain, Sarah Jefferies, Caroline Kelly, Jon Stobo, Anna Morris, Aoife Williamson, Anthony J. Chalmers
Format: Article
Language:English
Published: Elsevier 2018-01-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Glioblastoma
Poly(ADP-ribose) polymerase
Olaparib
Radiotherapy
O6-methylguanine methyltransferase
Dose escalation
Radiosensitizer
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630817300885
Description
Summary:Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.
ISSN:2405-6308

Similar Items